Boston Scientific Corporation: shareholders and insiders

BSXNYSEHealthcare · Surgical & Medical Instruments & Apparatus

Price

$43.03

November 17, 2026Market cap $63.9B

What Ploutos Investor adds for Boston Scientific

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 18, 2025 to Nov 6, 2026, from their own Form 4 filings.

13 Form 4s

Bought on the market

$10M

5 people

Sold on the market

$17M

2 people

From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan100%
  • The rest0%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $10M by 5 people·sold $15M by 1 person

  • 2025: no buys, sold $1.8M by 1 person
  • 2026: bought $10M by 5 people, sold $15M by 1 person
  • Nov 4, 2026Michael F MahoneyChairman, President & CEO
    Kind
  • Nov 4, 2026Michael F MahoneyChairman, President & CEO
    Kind
  • Nov 1, 2026Miriam O'SullivanSVP, Chief HR Officer
    Kind
  • Nov 1, 2026Miriam O'SullivanSVP, Chief HR Officer
    Kind
  • Sep 2, 2026Padraig Andrew O'ConnorEVP, Global Operations
    Kind
  • Sep 2, 2026Padraig Andrew O'ConnorEVP, Global Operations
    Kind
  • Aug 25, 2026Susan E MoranoDirector
    Kind
  • Aug 11, 2026Emily WoodworthSVP, Global Controller and CAO
    Kind
  • Aug 10, 2026Jonathan MonsonEVP and CFO
    Kind
  • Aug 5, 2026David C HabigerDirector
    Kind
  • Aug 4, 2026David C HabigerDirector
    Kind
  • Aug 3, 2026David C HabigerDirector
    Kind
  • Aug 3, 2026Michael F MahoneyChairman, President & CEO
    Kind
  • Aug 3, 2026Michael F MahoneyChairman, President & CEO
    Kind
  • Jul 31, 2026Edward J LudwigDirector
    Kind
  • Jul 31, 2026Joseph Michael FitzgeraldEVP & Group Pres, Cardiology
    Kind
  • Jul 1, 2026Jonathan MonsonEVP and CFO
    Kind
  • Jul 1, 2026Jonathan MonsonEVP and CFO
    Kind
  • May 28, 2026Michael F MahoneyChairman, President & CEO
    Kind
  • May 20, 2026David C Habiger
    Kind
  • May 20, 2026Edward J Ludwig
    Kind
  • May 20, 2026Cheryl Pegus
    Kind
  • May 19, 2026David C Habiger
    Kind
  • Feb 2, 2026Michael F MahoneyChairman, President & CEO
    Kind10b5-1
  • Feb 2, 2026Michael F MahoneyChairman, President & CEO
    Kind10b5-1

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 1, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by BSX's officers and directors from 2006 up to November 17, 2025, 20 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

2 Holders over 5%Aug 6, 2026 Latest filing
  • BlackRock, Inc.
    Share of class7.60%
  • Vanguard Capital Management
    Share of class7.47%
Fell to 5% or less (2)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • FMR3.10%Aug 6, 202613G/A
  • The Vanguard Group0.00%Mar 26, 202613G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • D.E. Shaw
    In the quarter-17%
  • AQR Capital
    In the quarter+151%
  • Citadel Advisors (Griffin)
    In the quarter+57%
  • Renaissance Technologies
    In the quarter-27%
  • Bridgewater (Dalio)
    In the quarter-1.1%
  • Glenview Capital
    In the quarter-38%
  • Point72 (Cohen)
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter-79%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 2.74% of its shares outstanding were held short, -1.7% since the report before.

Shares held short
40.71M
2.74%
Since the report before41.41M on Sep 30, 2026
-1.7%
2.6
15.74M
More days to cover thanof 4,578 US-listed companies with enough volume
30%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 9.14M
  • Nov 15, 2023: Shares held short 11.85M
  • Nov 30, 2023: Shares held short 9.24M
  • Dec 15, 2023: Shares held short 11.64M
  • Dec 29, 2023: Shares held short 9.35M
  • Jan 12, 2024: Shares held short 11.43M
  • Jan 31, 2024: Shares held short 10.87M
  • Feb 15, 2024: Shares held short 11.03M
  • Feb 29, 2024: Shares held short 9.44M
  • Mar 15, 2024: Shares held short 11.48M
  • Mar 28, 2024: Shares held short 12.43M
  • Apr 15, 2024: Shares held short 13.16M
  • Apr 30, 2024: Shares held short 13.94M
  • May 15, 2024: Shares held short 12.33M
  • May 31, 2024: Shares held short 13.38M
  • Jun 14, 2024: Shares held short 11.54M
  • Jun 28, 2024: Shares held short 11.25M
  • Jul 15, 2024: Shares held short 11.53M
  • Jul 31, 2024: Shares held short 10.80M
  • Aug 15, 2024: Shares held short 10.74M
  • Aug 30, 2024: Shares held short 11.02M
  • Sep 13, 2024: Shares held short 12.20M
  • Sep 30, 2024: Shares held short 10.92M
  • Oct 15, 2024: Shares held short 11.31M
  • Oct 31, 2024: Shares held short 12.91M
  • Nov 15, 2024: Shares held short 11.02M
  • Nov 29, 2024: Shares held short 12.25M
  • Dec 13, 2024: Shares held short 12.33M
  • Dec 31, 2024: Shares held short 14.52M
  • Jan 15, 2025: Shares held short 14.40M
  • Jan 31, 2025: Shares held short 10.45M
  • Feb 14, 2025: Shares held short 11.46M
  • Feb 28, 2025: Shares held short 12.87M
  • Mar 14, 2025: Shares held short 12.62M
  • Mar 31, 2025: Shares held short 13.10M
  • Apr 15, 2025: Shares held short 14.49M
  • Apr 30, 2025: Shares held short 15.71M
  • May 15, 2025: Shares held short 16.75M
  • May 30, 2025: Shares held short 17.02M
  • Jun 13, 2025: Shares held short 17.49M
  • Jun 30, 2025: Shares held short 19.05M
  • Jul 15, 2025: Shares held short 19.57M
  • Jul 31, 2025: Shares held short 16.27M
  • Aug 15, 2025: Shares held short 18.60M
  • Aug 29, 2025: Shares held short 18.99M
  • Sep 15, 2025: Shares held short 19.02M
  • Sep 30, 2025: Shares held short 19.40M
  • Oct 15, 2025: Shares held short 19.63M
  • Oct 31, 2025: Shares held short 19.45M
  • Nov 14, 2025: Shares held short 21.08M
  • Nov 28, 2025: Shares held short 18.73M
  • Dec 15, 2025: Shares held short 19.14M
  • Dec 31, 2025: Shares held short 20.01M
  • Jan 15, 2026: Shares held short 23.42M
  • Jan 30, 2026: Shares held short 28.28M
  • Feb 13, 2026: Shares held short 26.64M
  • Feb 27, 2026: Shares held short 26.26M
  • Mar 13, 2026: Shares held short 25.44M
  • Mar 31, 2026: Shares held short 23.53M
  • Apr 15, 2026: Shares held short 25.61M
  • Apr 30, 2026: Shares held short 28.64M
  • May 15, 2026: Shares held short 31.42M
  • May 29, 2026: Shares held short 57.49M
  • Jun 15, 2026: Shares held short 29.75M
  • Jun 30, 2026: Shares held short 27.94M
  • Jul 15, 2026: Shares held short 28.28M
  • Jul 31, 2026: Shares held short 22.28M
  • Aug 14, 2026: Shares held short 27.62M
  • Aug 31, 2026: Shares held short 48.17M
  • Sep 15, 2026: Shares held short 46.50M
  • Sep 30, 2026: Shares held short 41.41M
  • Oct 15, 2026: Shares held short 40.71M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading32.9% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 32.9% of the shares in the reported trades were short sales, against 39.1% in the 14 before.

Last 14 sessionsOct 29, 2026 – Nov 17, 2026
32.9%
The 14 beforeOct 9, 2026 – Oct 28, 2026
39.1%
Change
-6.2 pts
Short sales a dayon average, of 7.40M shares
2.44M
More than atof 3,666 US-listed companies, same days
7%
Median of alleight in ten from 34.6% to 63.7%
50.3%
  • Oct 9, 2026: Short sales 30.5%
  • Oct 12, 2026: Short sales 41.2%
  • Oct 13, 2026: Short sales 41.7%
  • Oct 14, 2026: Short sales 44.5%
  • Oct 15, 2026: Short sales 34.1%
  • Oct 16, 2026: Short sales 41.4%
  • Oct 19, 2026: Short sales 35.4%
  • Oct 20, 2026: Short sales 41.9%
  • Oct 21, 2026: Short sales 51.2%
  • Oct 22, 2026: Short sales 53.8%
  • Oct 23, 2026: Short sales 52.6%
  • Oct 26, 2026: Short sales 27.5%
  • Oct 27, 2026: Short sales 22.7%
  • Oct 28, 2026: Short sales 37.8%
  • Oct 29, 2026: Short sales 23.5%
  • Oct 30, 2026: Short sales 27%
  • Nov 2, 2026: Short sales 36.7%
  • Nov 3, 2026: Short sales 41.6%
  • Nov 4, 2026: Short sales 37.1%
  • Nov 5, 2026: Short sales 36.6%
  • Nov 6, 2026: Short sales 39.2%
  • Nov 9, 2026: Short sales 44.8%
  • Nov 10, 2026: Short sales 34.6%
  • Nov 11, 2026: Short sales 29.2%
  • Nov 12, 2026: Short sales 31.2%
  • Nov 13, 2026: Short sales 25%
  • Nov 16, 2026: Short sales 25.3%
  • Nov 17, 2026: Short sales 24.5%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

2.71M Insiders' shares0.18% Of the company
  • Michael F MahoneyChairman, President & CEO
    Directly1.86M
  • Joseph Michael FitzgeraldEVP & Group Pres, Cardiology
    Directly283.3K
  • Daniel J. BrennanEVP and CFO
    Directly225.8K
  • Jonathan MonsonEVP and CFO
    Directly49.0K
  • Eric Francis Yves ThepautEVP & Pres, Eur, Mid-East, Afr
    Directly31.4K
  • Vance R BrownSVP, GC and Corp. Secretary
    Directly31.4K
  • Edward J LudwigDirector
    Directly30.4K
  • Wendy CarruthersEVP, Human Resources
    Directly29.3K
  • Jeffrey B. MirvissEVP&Pres, Periph Intervent
    Directly25.8K
  • Ellen M ZaneDirector
    Directly24.1K
  • Arthur C ButcherEVP& Grp Pres, MedSurg & APAC
    Directly23.6K
  • Miriam O'SullivanSVP, Chief HR Officer
    Directly21.3K
  • John Bradley SorensonEVP, Global Operations
    Directly18.7K
  • David C HabigerDirector
    Directly17.2K
  • Susan E MoranoDirector
    Directly13.8K
  • Padraig Andrew O'ConnorEVP, Global Operations
    Directly7,892
  • Emily WoodworthSVP, Global Controller and CAO
    Directly6,053
  • Yoshiaki FujimoriDirector
    Directly2,081
  • Cheryl PegusDirector
    Directly1,770
  • Charles J DockendorffDirector
    Directly–

A lower bound: it counts only the 20 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

10b5-1 trading plans

Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.

1 Adopted in the last 12 months15 Filings read
  • Michael F. MahoneyChairman and Chief Executive Officer
    What happenedAdoptedAug 12, 2026
    Shares98.8K
  • Michael F. MahoneyChairman and Chief Executive Officer
    What happenedEndedFeb 19, 2026
    Shares–
  • Miriam O’SullivanSenior Vice President and Chief Human Resources Officer
    What happenedAdoptedNov 13, 2025
    Shares14.9K
  • Michael F. MahoneyChairman and Chief Executive Officer
    What happenedAdoptedAug 29, 2025
    Shares–
  • Arthur C. ButcherExecutive Vice President and Group President, MedSurg and Asia Pacific
    What happenedAdoptedAug 28, 2025
    Shares–
  • Jeffrey B. MirvissSenior Vice President and President, Peripheral Interventions
    What happenedAdoptedAug 28, 2025
    Shares–
  • Ellen M. Zaneindependent member of our Board of Directors
    What happenedAdoptedJul 25, 2025
    Shares–
  • Emily M. WoodworthSenior Vice President, Global Controller and Chief Accounting Officer
    What happenedAdoptedNov 29, 2024
    Shares–
  • Jeffrey B. MirvissSenior Vice President and President, Peripheral Interventions
    What happenedAdoptedNov 21, 2024
    Shares–
  • Vance R. BrownSenior Vice President, General Counsel and Corporate Secretary
    What happenedAdoptedNov 21, 2024
    Shares19.3K

As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.

Executive pay

From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.

2025 Latest year6 Years on record

$24M

Actually paid: $33M

$5.8M

Actually paid: $5.9M

$265

Peers: $148

Adjusted Net Sales

$19.9B

From the proxy statement (DEF 14A) of Mar 18, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A

The shareholders' vote on pay

The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.

90.8% For in 20265 Votes on record
  • 2026May 5, 2026
    For
    90.8%
  • 2024May 6, 2024
    For
    92.7%
  • 2023May 9, 2023
    For
    92.6%
  • 2022May 6, 2022
    For
    89.7%
  • 2021May 11, 2021
    For
    92.6%

From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

54 ETFs holding it3.99% The largest weight (IHI)
  • IHIiShares U.S. Medical Devices ETF
    Weight in the fund3.99%
  • IYHiShares U.S. Healthcare ETF
    Weight in the fund1.14%
  • XLVState Street(R) Health Care Select Sector SPDR(R) ETF
    Weight in the fund1.10%
  • BLCRiShares Large Cap Core Active ETF
    Weight in the fund1.02%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.99%
  • IXJiShares Global Healthcare ETF
    Weight in the fund0.82%
  • MGKVanguard Mega Cap Growth Index Fund
    Weight in the fund0.28%
  • IWXiShares Russell Top 200 Value ETF
    Weight in the fund0.25%
  • USMViShares MSCI USA Min Vol Factor ETF
    Weight in the fund0.24%
  • SCHVSchwab U.S. Large-Cap Value ETF
    Weight in the fund0.23%

54 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

1,474 Managers, Q2 2026$57.6B Value of their positions
  • Q3 2025: Managers 1,718
  • Q4 2025: Managers 1,792
  • Q1 2026: Managers 1,683
  • Q2 2026: Managers 1,474

Institutional investors by quarter

The fund managers holding BSX, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 1,474 managers held 1.34B shares, worth $57.6B. During the quarter 146 opened a position, 355 closed one, 584 added and 608 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter-1.6%
  • Vanguard Capital Management
    In the quarter+0.7%
  • State Street
    In the quarter+3.1%
  • Primecap Management
    In the quarter+55%
  • FMR
    In the quarter-38%
  • Geode Capital Management
    In the quarter+0.5%
  • Vanguard Portfolio Management
    In the quarter
  • D.E. Shaw
    In the quarter+4.7%
  • Massachusetts Financial Services
    In the quarter+126%
  • JPMorgan Chase
    In the quarter-28%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

The full analysis

What do Boston Scientific's filings show?

Who buys and sells is one part of Boston Scientific's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about BSX's shareholders

Didn't find what you were looking for?

Ask us
Have BSX's insiders bought or sold?

From Jun 1, 2026 to Nov 6, 2026 Boston Scientific's insiders bought $9.5M and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.

Which well-known managers hold BSX?

8 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $1.1B.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.